Media stories about Aldeyra Therapeutics (NASDAQ:ALDX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.3330630749611 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) opened at $8.85 on Thursday. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $11.90. The firm has a market capitalization of $169.19, a PE ratio of -6.32 and a beta of 0.46. The company has a quick ratio of 20.35, a current ratio of 20.35 and a debt-to-equity ratio of 0.02.
Several analysts have weighed in on ALDX shares. Zacks Investment Research cut Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Seaport Global Securities started coverage on Aldeyra Therapeutics in a report on Friday, January 26th. They issued a “buy” rating and a $13.00 price target on the stock. ValuEngine raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $27.00 price target on shares of Aldeyra Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $16.79.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.